Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
---|---|
Information provided by: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT00344188 |
This study will examine the natural history of Leishmanial infections and their treatments. It will provide an opportunity for NIAID staff to learn more about leishmaniasis and perhaps to improve diagnostic tests for these infections. Patients between 2 and 80 years of age with known or suspected leishmaniasis are eligible for this study.
Participants will have routine blood tests and a biopsy to confirm leishmanial infection. The biopsy procedure will be determined by the type of infection-local cutaneous leishmaniasis (LCL), mucocutaneous leishmaniasis (MCL) or visceral leishmaniasis (VL). CL will be confirmed with a punch biopsy, in which a cookie-cutter type razor is used to remove a small circular piece of skin tissue. MCL will be confirmed using a thin flexible tube inserted into the nose. This tube is used to examine the nose and upper airway and to remove a tissue sample, if an affected area is seen. VL will be confirmed with either a bone marrow or liver biopsy or a splenic aspirate. For these procedures, a small tissue sample is withdrawn through a needle placed in the hipbone, liver or spleen, respectively. Some patients may also have a skin test for leishmaniasis similar to tuberculin skin testing.
Treatment and length of hospital stay are determined by the type of infection. CL may be treated with Pentostam, amphotericin, amphotericin B, itraconazole or ketoconazole; ML with amphotericin B, or encapsulated amphotericin; and VL with Pentostam or encapsulated amphotericin. Pentostam is infused daily for 18 to 28 doses, most as an outpatient. Blood is drawn 3 times a week for safety tests and an electrocardiogram is done 2 to 3 times a week to monitor heart rhythm. Amphotericin B is infused every day or every other day for about 30 doses, all on an inpatient basis. Patients undergo hydration (infusion of a large amount of fluid) just before and immediately after each infusion to protect the kidneys. Blood is drawn every other day and urine samples are collected occasionally for routine urinalysis. Encapsulated amphotericin is infused every other day, on an outpatient basis. Blood is generally drawn every other day to every 2 days and urinalyses are done periodically. Itraconazole and ketoconazole are taken orally for at least 1 to 3 months, with blood drawn every 2 to 3 weeks.
Patients may be asked to have photographs taken before, during and after treatment to document progress. They may also be asked to provide extra blood samples for research purposes, either through a vein in the arm or through apheresis, a method for collecting large numbers of cells. For apheresis, whole blood is collected through a needle in an arm vein and circulated through a machine that separates it into its components. The desired cells are then removed, and the rest of the blood is returned to the body, either through the same needle used to draw the blood or through a second needle in the other arm.
Patients with cutaneous leishmaniasis will have a follow-up clinic visit 2 weeks to 3 months after treatment is completed. If there are no complications, their participation will end at that time. Patients with mucocutaneous leishmaniasis and visceral leishmaniasis will be followed every 3 to 6 months indefinitely for routine evaluations and re-treatment if the infection recurs.
Condition |
---|
Leishmaniasis |
Study Type: | Observational |
Official Title: | Diagnosis and Treatment of Leishmanial Infections |
Estimated Enrollment: | 75 |
Study Start Date: | August 2001 |
Over the past 25 years, we have carried out studies, both here at the NIH and abroad, on patients with leishmaniasis. Originally, a major objective was to evaluate cell-mediated immune function in patients with different clinical forms of the disease. A secondary objective was to isolate and have available different strains of Leishmanial parasites for various laboratory studies by members of LPD. In recent years, immunologic studies of patients have been done less frequently. Because local physicians do not have experience in diagnosis and treatment of leishmaniasis, and because side effects from the currently recommended drug (Pentostam) are quite common, this protocol was continued partly as a service to the local medical community. The reason for now initiating a new protocol on leishmaniasis is to define more accurately the type of protocol: namely, to study the natural history of Leishmanial infections and their treatment and to provide training for the NIAID medical staff.
Ages Eligible for Study: | 2 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Individuals of either sex must be between the ages of 2 and 80 years.
Individuals must have a parasitologic diagnosis confirmed by culture or PCR at the NIH. In some instances, a diagnosis established at some other facility, or based upon clinical and convincing histopathological evidence may allow inclusion.
EXCLUSION CRITERIA:
Individuals who are pregnant or breast feeding, who do not have a life-threatening form of this disease, will be excluded from this protocol until termination of pregnancy (birth or otherwise). Those with life-threatening leishmaniasis will be offered treatment.
Contact: Patient Recruitment and Public Liaison Office | (800) 411-1222 | prpl@mail.cc.nih.gov |
Contact: TTY | 1-866-411-1010 |
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
Bethesda, Maryland, United States, 20892 |
Study ID Numbers: | 010238, 01-I-0238 |
Study First Received: | June 23, 2006 |
Last Updated: | July 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00344188 |
Health Authority: | United States: Federal Government |
Cutaneous Leishmaniasis Leishmanial Infection Leishmaniasis |
Leishmaniasis Protozoan Infections Skin Diseases, Infectious Skin Diseases Parasitic Diseases |
Skin Diseases, Parasitic Sarcomastigophora Infections Mastigophora Infections Infection |